ArticleMovement disorders clinical practice2025
Rapid Progression and Shorter Survival in Indians Affected with Probable MSA: A Prospective Cohort Study.
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety and Efficacy of Mesenchymal Stem Cell Therapy in Multiple System Atrophy: Systematic Review.Biologics : targets & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple system atrophy (MSA) is a fatal alpha-synucleinopathy characterized by variable combinations of parkinsonism and autonomic and cerebellar dysfunctions.
objectiveWe aimed to prospectively study the natural history of probable MSA, including cardiovascular autonomic dysfunction (CAD) and serum alpha-synuclein.
methodsSixty probable MSA patients (MSA-P = 19; MSA-C = 41) and 30 age-and-gender-matched healthy controls were recruited. Disease severity (UPDRS III, UMSARS I, II, IV), CAD, and serum alpha-synuclein (ELISA) were assessed at baseline, 6-month (6 M-FU), and 12-month (12 M-FU) follow-ups. Survival probabilities (Kaplan-Meir analysis) and prognostic factors (Cox proportional hazards analysis) were assessed at the study's end period.
resultsTotal serum alpha-synuclein was higher in MSA patients than controls (P < 0.001). There was severe CAD in MSA patients at baseline (P < 0.001), which further deteriorated at 12 M-FU (P < 0.01). A greater proportion of MSA-P patients had a dopaminergic benefit than MSA-C patients (P < 0.001). CAD had a positive correlation with serum alpha-synuclein and disease severity. UPDRS III and UMSARS II scores were higher at follow-ups (P < 0.001). Disease progression was more rapid in MSA-C patients than MSA-P patients (P < 0.001). The median time to one-person support for walking and activities of daily living (ADL), wheelchair support, bedbound state, and death were 27, 48, 66, and 70 months, respectively. The probabilities of needing one-person support and wheelchair support were lower in MSA-P patients than MSA-C (P = 0.005; P = 0.03), whereas the probabilities of bedbound state and death were similar.
conclusionsProbable MSA patients had a rapid progression, autonomic failure, and a shorter survival of 5.8 years in this Asian-Indian cohort compared to the other MSA cohorts worldwide (9-10 years). MSA-P patients had a better prognosis than MSA-C. Elevated serum alpha-synuclein and its positive correlation with CAD provide evidence for its role as a potential biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.